Wed, September 11, 2024

David Amsellem Downgraded (SUPN) to Hold and Decreased Target to $36 on, Sep 11th, 2024

David Amsellem of Piper Sandler, Downgraded "Supernus Pharmaceuticals, Inc." (SUPN) to Hold and Decreased Target from $41 to $36 on, Sep 11th, 2024.

David, nor any peers, have made any analyst calls on SUPN in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30